Current News
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 07, 2014
Med BioGene Announces Publication of Data Demonstrating Independent Validation of GeneFx® Lung
January 09, 2014
Med BioGene Announces Dismissal of Litigation With Signal Genetics LLC and Respira Health LLC
| Additional International Exposure for MBI’s Commercialization Partner
Helomics™ Corporation, Med BioGene’s partner responsible for the commercialization of GeneFx™ Lung, has announced that Neil Campbell, their President and Chief Executive Officer, will provide an overview of the personalized healthcare landscape, the Company’s business, and it’s comprehensive tumorprofiling technologies. The presentation will take place at the “Personalized Medicine World Conference” to be held in Oxford, UK between April 15th and 17th, 2015. Helomics™ Corporation is a privately held personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services. Helomics™ entered into an agreement with Med BioGene Inc. in 2011 to license and commercialize MBI’s GeneFx™ Lung product. For further information visit www.helomics.com
|
|
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer